© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
September 16, 2021
Tucatinib is indicated to treat adults with advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have already received at least 1 anti-HER2-based regimen in the metastatic setting.
Survey participants saw potential for immunotherapy use in earlier stages of several diseases, including melanoma, lung cancer, and bladder or urothelial cancer.
September 13, 2021
The results of a 5-year follow-up study comparing trastuzumab (Ontruzant) and reference medicine trastuzumab show comparable cardiac safety profiles and long-term efficacy.
September 10, 2021
Study suggests potentially expanding the use of immunotherapies in the elderly, a population in whom these therapies may be under-prescribed.
September 08, 2021
Ado-trastuzumab (Kadcyla, Genentech) was approved by the FDA in 2019 for the adjuvant treatment of patients with human epidermal growth factor receptor 2-positive early breast cancer.
This drug class works by interfering with the ability of cancer cells to repair themselves after experiencing damage to their DNA, but how PARP inhibitors selectively kill cancer cells was previously unknown.
September 01, 2021
Atezolizumab was granted accelerated approval for the mTNBC indication in March 2019, making it the first immunotherapy agent to be approved in this setting.
August 24, 2021
This research lays the foundation for future clinical trials aimed at investigating whether moderate to vigorous exercise can minimize “chemo brain,” which is a decline in cognitive function many patients with breast cancer experience.
August 19, 2021
As health care costs rise and cost-sharing increases, treatment-associated expenses will continue to burden patients.
August 18, 2021
Approved by the FDA on June 29, 2020, the pertuzumab, trastuzumab, and hyaluronidase-zzxf combination therapy with chemotherapy offers several advantages to the standard treatment of pertuzumab plus trastuzumab with chemotherapy for breast cancers with HER2 overexpression.